Total
0
Shares
Neurotech (ASX:NTI) - Chairman, Brian Leedman - The Market Herald
Chairman, Brian Leedman
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neurotech (NTI) is set to pocket $3.5 million via an underwritten exercise options shortfall and an oversubscribed private placement
  • The placement's lead, the Merchant Opportunities Fund, is set to underwrite the shortfall from the exercise of around 26.1 million listed options, with Neurotech set to collect $1.56 million as a result
  • The remaining $2 million is owed to binding commitments from sophisticated and professional investors who were offered just over 36.3 million fully paid ordinary shares at 5.5 cents each
  • Proceeds from the placement and underwriting are expected to go towards developing the Mente home therapy device and research into the use of cannabinoids to treat neurological disorders
  • NTI closed the day down 11.3 per cent at 6.3 cents per share

Neurotech (NTI) is set to pocket $3.5 million via an underwritten exercise options shortfall and an oversubscribed private placement.

The healthcare player reached an agreement with the Merchant Opportunities Fund to underwrite the shortfall from the exercise of 26,122,966 listed options, which are due to expire at the end of March.

As a result, Neurotech is set to collect $1.56 million from the exercise at six cents apiece.

The remaining funds stem from binding commitments made via a $2 million placement, under which 36,363,637 fully paid ordinary shares were offered to sophisticated and professional investors at 5.5 cents each.

Proceeds from these activities are set to go towards executing its existing business plan, including the continued development and marketing of its Mente home therapy device and research into the use of cannabinoids to treat neurological disorders including autism and ADHD.

Its upcoming phase one and two human clinical trials through Monash Children's Hospital will focus on paediatric patients who have autism and related disorders and are tipped to start at the end of this quarter.

Placement shares are expected to settle on or about Thursday, March 11, and allotted on Monday, March 15, 2021.

Neurotech will also issue the Merchant Opportunities Fund 10 million share options as part of its fee for the underwriting.

Neurotech Chairman Brian Leedman said he was pleased to secure the funding.

NTI closed the day down 11.3 per cent at 6.3 cents per share.

NTI by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" TGA fast tracks evaluation of Telix Pharmaceuticals’ (ASX:TLX) cancer imaging product

The Theraputic Goods Administration (TGA) has commenced a priority evaluation process for Telix Pharmaceuticals’ (TLX) prostate cancer imaging product, Illuccix.
Pharmaxis (ASX:PXS) - CEO, Gary Phillips (left) - The Market Herald

" Pharmaxis (ASX:PXS) to raise $4.4M via placement

Pharmaxis (PXS) has received firm commitments to raise $4.4 million through a placement.
Musgrave enters $18M joint venture with Evolution

" Capral (ASX:CAA) urges shareholders to accept buyout offer from Allegro

Aluminium company Capral (CAA) has been approached with an indicative proposal from Allegro to buy 100 per cent of company shares at $7
Universal Biosensors (ASX:UBI) - CEO, John Sharman - The Market Herald

" Universal Biosensors (ASX:UBI) toasts new distribution agreement for wine testing device

Universal Biosensors (UBI) has entered into a non-exclusive agreement with Singularity SpA to distribute its wine testing platform device in Chile.